Emeryville, California, December 3, 2019 – Eureka Therapeutics, Inc., a clinical stage biotechnology company developing novel T-cell therapies to treat cancers, today announced that new clinical data from its first-in-human study of ET019003, an anti-CD19 T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL), will be presented in a poster session at the 61st American Society of Hematology (ASH) Annual Meeting on December 8, 2019. ET019003 is engineered by incorporating a co-stimulatory molecule into T-cells expressing an anti-CD19 antibody T-cell receptor (AbTCR) core structure, representing the next generation of Eureka’s novel T-cell therapy generated with the ARTEMIS™ T-cell platform.
“We are excited to be selected for poster presentation at the 2019 ASH Meeting,” said Dr. Cheng Liu, Founder & CEO of Eureka Therapeutics. “This is significant recognition of the progress we are making in the development of novel T cell therapies from our ARTEMIS™ platform, and we look forward to sharing additional updates from our additional programs at the conference.”
Details of the poster presentation are as follows:
Title: First-in-Human Study of ET019003, a Next Generation Anti-CD19 T-Cell
Therapy, in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma (r/r
DLBCL)
Publication: 2870
Session: 626
Date: Sunday, December 8, 2019
Time: 6:00 – 8:00pm EST
Location: Orange County Convention Center, Hall B
Presenter: Pengcheng He, the First Affiliated Hospital of Xi’an Jiaotong University, China
The ASH abstract is now available at www.hematology.org. The poster presentation will include additional data not available in the abstract.
ABOUT EUREKA THERAPEUTICS, INC.
Eureka Therapeutics, Inc. is a privately held clinical stage biotechnology company focused on developing novel T-cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS™ AbTCR T-cell receptor platform and E-ALPHA® antibody discovery platform for the discovery and development of potentially safer and more effective T-cell therapies for the treatment of multiple solid and hematologic tumors. ET140202, the Company’s lead asset, is currently in a Phase I/II US multicenter clinical trial in patients with advanced hepatocellular carcinoma (HCC).
Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit www.eurekatherapeutics.com.
CONTACTS:
Eureka Therapeutics, Inc.
Natalie Liu
Investor Relations
510-722-8720
IR@eurekainc.com
Media
KKH Advisors
Kimberly Ha
917-291-5744
kimberly.ha@kkhadvisors.com
